QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.106.013136v1 35/4/533    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vincent, S. H. Articles by Herman, G. A. Search for Related Content PubMed PubMed Citation Articles by Vincent, S. H. Articles by Herman, G. A.

Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [¹⁴C]Sitagliptin in Humans

Departments of Drug Metabolism (S.H.V., J.R.R., C.S.E., B.Z., S.X.) and Clinical Pharmacology (D.E., P.L., K.G., J.A.W., G.A.H.), Merck Research Laboratories, Rahway, New Jersey; Department of Drug Metabolism, Merck Research Laboratories, West Point, Pennsylvania (A.J.B., W.Z., L.C.); and Clinical Pharmacology Associates, Miami, Florida (S.D., K.L.)

The metabolism and excretion of [¹⁴C]sitagliptin, an orally active, potent and selective dipeptidyl peptidase 4 inhibitor, were investigated in humans after a single oral dose of 83 mg/193 µCi. Urine, feces, and plasma were collected at regular intervals for up to 7 days. The primary route of excretion of radioactivity was via the kidneys, with a mean value of 87% of the administered dose recovered in urine. Mean fecal excretion was 13% of the administered dose. Parent drug was the major radioactive component in plasma, urine, and feces, with only 16% of the dose excreted as metabolites (13% in urine and 3% in feces), indicating that sitagliptin was eliminated primarily by renal excretion. Approximately 74% of plasma AUC of total radioactivity was accounted for by parent drug. Six metabolites were detected at trace levels, each representing <1 to 7% of the radioactivity in plasma. These metabolites were the N-sulfate and N-carbamoyl glucuronic acid conjugates of parent drug, a mixture of hydroxylated derivatives, an ether glucuronide of a hydroxylated metabolite, and two metabolites formed by oxidative desaturation of the piperazine ring followed by cyclization. These metabolites were detected also in urine, at low levels. Metabolite profiles in feces were similar to those in urine and plasma, except that the glucuronides were not detected in feces. CYP3A4 was the major cytochrome P450 isozyme responsible for the limited oxidative metabolism of sitagliptin, with some minor contribution from CYP2C8.

This article has been cited by other articles:

				D. M. Bloomfield, R. Krishna, D. Hreniuk, L. Hickey, K. Ghosh, A. J. Bergman, J. Miller, M. J. Gutierrez, R. Stoltz, K. M. Gottesdiener, et al. A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects J. Clin. Pharmacol., August 1, 2009; 49(8): 937 - 946. [Abstract] [Full Text] [PDF]

				A. J. Bergman, J. Cote, A. Maes, J. J. Zhao, B. A. Roadcap, L. Sun, R. J. Valesky, A. Yang, B. Keymeulen, Z. Mathijs, et al. Effect of Sitagliptin on the Pharmacokinetics of Simvastatin J. Clin. Pharmacol., April 1, 2009; 49(4): 483 - 488. [Full Text] [PDF]

				C. W. Chia and J. M. Egan Incretin-Based Therapies in Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3703 - 3716. [Abstract] [Full Text] [PDF]

				D. Q. Pham, A. Nogid, and R. Plakogiannis Sitagliptin: A novel agent for the management of type 2 diabetes mellitus Am. J. Health Syst. Pharm., March 15, 2008; 65(6): 521 - 531. [Abstract] [Full Text] [PDF]